A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 5.66 USD -1.05%
Market Cap: 206.1m USD

Armata Pharmaceuticals Inc
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Armata Pharmaceuticals Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Operating Expenses
-$40m
CAGR 3-Years
-5%
CAGR 5-Years
-13%
CAGR 10-Years
-12%
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$22.7B
CAGR 3-Years
-2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.6B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.8B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$5.6B
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$8.4B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-14%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
204.9m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.81 USD
Overvaluation 50%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Operating Expenses?
Operating Expenses
-40m USD

Based on the financial report for Jun 30, 2025, Armata Pharmaceuticals Inc's Operating Expenses amounts to -40m USD.

What is Armata Pharmaceuticals Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-12%

Over the last year, the Operating Expenses growth was 19%. The average annual Operating Expenses growth rates for Armata Pharmaceuticals Inc have been -5% over the past three years , -13% over the past five years , and -12% over the past ten years .

Back to Top